These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15912848)

  • 1. [Transdermal systems].
    Lipp HP
    Krankenpfl J; 2005; 43(1-3):61. PubMed ID: 15912848
    [No Abstract]   [Full Text] [Related]  

  • 2. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol.
    Cichewicz DL; Welch SP; Smith FL
    Eur J Pharmacol; 2005 Nov; 525(1-3):74-82. PubMed ID: 16288738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
    Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
    Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
    J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.
    Yassen A; Olofsen E; Romberg R; Sarton E; Teppema L; Danhof M; Dahan A
    Clin Pharmacol Ther; 2007 Jan; 81(1):50-8. PubMed ID: 17185999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma buprenorphine concentrations after the application of a 70 microg/h transdermal patch in dogs. Preliminary report.
    Andaluz A; Moll X; Ventura R; Abellán R; Fresno L; García F
    J Vet Pharmacol Ther; 2009 Oct; 32(5):503-5. PubMed ID: 19754919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [No potentiation of fentanyl by use of transdermal buprenorphine in patients undergoing fast-track anesthesia for open-heart surgery].
    Freye E; Hartung E; Levy JV
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2006 Feb; 41(2):86-92. PubMed ID: 16493560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
    Koltzenburg M; Pokorny R; Gasser UE; Richarz U
    Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patchs: the success of transdermal administration].
    Derrien E
    Rev Infirm; 2004 Apr; (100):23-30. PubMed ID: 15222181
    [No Abstract]   [Full Text] [Related]  

  • 13. Transdermal fentanyl.
    Med Lett Drugs Ther; 1992 Oct; 34(881):97-8. PubMed ID: 1406448
    [No Abstract]   [Full Text] [Related]  

  • 14. Avoiding medication errors with transdermal nitroglycerin products.
    Falbe WJ; Mickle TR
    Am J Hosp Pharm; 1986 Nov; 43(11):2738, 2740. PubMed ID: 3099566
    [No Abstract]   [Full Text] [Related]  

  • 15. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal buprenorphine in the treatment of chronic pain.
    Sittl R
    Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How oral contraceptives and drugs interact].
    Kuhl H
    Geburtshilfe Frauenheilkd; 1994 Feb; 54(2):M23-30. PubMed ID: 8174908
    [No Abstract]   [Full Text] [Related]  

  • 18. Ageusia associated with transdermal nitroglycerin.
    Ewing RC; Janda SM; Henann NE
    Clin Pharm; 1989 Feb; 8(2):146-7. PubMed ID: 2492914
    [No Abstract]   [Full Text] [Related]  

  • 19. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA; Norman H; Doherty M; Walker AM
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
    Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
    Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.